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Factor XIII Inhibits Epidermal Cell Migration In Vitro* 
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Department of Medicine, Welsh National School of Medicine, Cardiff, U.K. 
The effect of a factor XIII preparation on active epi-
dermal cell migration in vitro has been studied using 
both floating and attached types of human skin explants 
in short-term maintenance cultures. In both types of 
experiment the factor XIII preparation proved to have 
an i nhibitory effect on epidermal cell migration in a 
dose-dependent fashion. This effect was shown to be 
independent of both the presence of fibrin and the con-
centration of calcium ion in the medium. The prepara-
tion also showed inhibition of the proliferation of epi-
dermal cells in cell culture. 
Factor XIII, the fibrin-stabilizing factor, is an essential com-
ponent of the clotting cascade that is activated by thrombin. It 
cross-links unstable fibrin to a stable form via its transglutam-
inase activity [1,2]. Factor XIII is also thought to have func-
tions in cross-linking fibronectin to itself [3], to fibrin [ 4], and 
to collagen [5], as well as increasing the capabili ty of these 
potential substrates to support fibroblast adhesion [6]. 
Factor XIII, prepared from human blood or placenta, is used 
in the t reatment of the bleeding tendency in congenital and 
acquired factor XIII deficiency [7] but because of its fibrin-
stabilizing quali ties has also been considered to have an impor-
tant role in t he promotion of wound healing. Although there 
have been some reports which suggest the involvement of factor 
XIII in wound healing [7- 10], there have been only a few 
published studies and these have presented evidence of the 
effects o n fibroblasts [8] or granulation tissue [11] in wounds. 
There have been no previous published studies on t he effects 
of facto r XIII on the epidermis. 
Epidermal cell migration is a vital first step in the reepithe-
Iialization of wounds. It is closely simulated by epidermal cell 
migration in vitro from skin explants [12]. 
As part of a program to investigate the effects of factor XIII 
on wound healing, we have studied the effects on epidermal cell 
migration and epidermal cell production in vitro and now wish 
to report these findings. 
MATERIALS AND METHODS 
Bioassay 1 (Epidermal Cell Migration from Floating Explants) 
Normal human skin was obtained wi th a Davies keratotome (Chas. 
F. Thackray Ltd., Leeds, U.K.) set at 0.33 mm, from the thighs of 5 
healthy male vo luntee rs, aged 35- 45 years, who had given their in-
formed consent. The thin sheets of skin were divided into rectangular 
exp lants approximately 4 x 6 mm. 
The explants were previously treated by fib rinogen as fo llows. Ex-
p la n ts were placed dermal side upward in plastic dishes. Human fibrin-
ogen ( 4 rng/ml) (JMCO, Stockholm, Sweden) and subsequently bovine 
t hrombin (10 U/ml) (Sigma, Poole, U.K.) were applied to the explants. 
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Excess solution was sucked off and fibrinogen was left clotted around 
t he explants. These explants were taken from the bottom of the dish 
and then floated, epidermis upward, in either Dulbecco's modified 
Eagle's minimum essential medium (MEM) (Flow Laboratories, Irvine, 
U.K.) or Ca++ free Eagle's MEM (Flow Laboratories) with 10% feta l 
calf serum (FCS) (GJBCO Europe Ltd., Paisley, U.K.) at concentra-
t ions of 0.1, 1.0, and 10.0 IU/ml (1 IU is equivalent to the activity of 
facto r XIII present in 1 ml of fresh human cit rated plasma). The factor 
X III preparation was obtained from Behringwerk AG, West Germany. 
Two milliliters of medium and 1 or 2 explants were placed in each 
disposable plastic Petri dish (Flow Laboratories) and incubated fo r 48 
h at 37'C. In some experiments we omi tted the addit ion of FCS or 
previous fibrinogen t reatment. 
After 48-h incubation the explants were removed and fixed in 10% 
formalin, dehydrated, and embedded by rout ine methods. They were 
sectioned and stained with hematoxylin and eosin. Five sections at 
150-Jlm intervals along each explant were examined microscopically. 
From the edge of the explants, cells were found to migrate around 
the dermis in a thin cellular layer as well as growing laterally and 
forming pennant-like extensions. We measured the area of epidermal 
ce ll migration around the dermis by counting the nuclei of cells or by 
calculating the actual area of outgrowth with a digitizer tablet (Sum-
magraphics, Connecticut, USA) interfaced with a Hewlett Packard 85 
compute r. 
B1:oassay 2 (Epidermal Cell Migration from Attached Explant.~) 
Human skin sheets obtained with a keratome as described previously 
were cut into small skin fragments (less than 1 mm2 ). T hese fragments 
were placed in plastic dishes and treated with fibrin ogen using the 
same method described in Bioassay 1, except that the explants were 
left on t he dishes. Explants were incubated in the same medium as in 
Bioassay 1 and this was changed every t hird day. In some experiments, 
we omi tted the addi t ion of FCS or previous fibrinogen treatment, and 
coverslips were used to fix the skin fragments to the dish. 
After 7 days of incubation, the dishes were fixed with 10% formalin 
and stained with 1% aqueous crystal violet in situ. The areas of 
migrated epidermal cells on the bottoms of the dishes were measured 
planimetrically (Reiss, G.D.R.) for each explant by projection of the 
image onto graph paper, using a microscope side arm (San kei, Japan). 
Bioassay 3 (Epidermal Cell Culture) 
Epidermal cell culture was carried out according to the modification 
of Dykes et al [13] of the method of Rheinwald and Green (14]. Briefly, 
the suspensions of human epidermal ce lls were plated onto the 30-mm 
dishes (Flow Laboratories) with or without glass coverslips. Calcium 
ion-free MEM supplemented with 5% FCS, (final c++ concentration 
0.2 mM ), hydrocort isone (0.4 11g/ml; Sigma, U.K.), cholera toxin (10 
ng/ml; Becton Dickinson), and penicillin-streptomycin (Flow Labora-
tories) was used. The epidermal ce lls were cocultivated with mitomycin 
C (Sigma, U.K.)- inhibi ted 3T3 mouse embryo fibroblast ce lls as a 
"feeder layer." After incubation at 37'C for 24 h, the medium was 
replaced with the medium supplemented with various concentrations 
of factor XIII (0.01, 0.1, 1.0, and 10.0 IU/ml) and the medium was 
changed again 3 days later. Seven days after inoculation, dishes without 
covers! ips were fixed, stained in situ with 1% aqueous crystal violet, 
and the number of cells counted microscopically. The dishes with 
coverslips were pulsed for 2 h with [methyl-3H)thymidine (3 ,uCi/ml, 
sp act 24 Ci/ mmol, Amersham International PLC, Amersham, U.K.), 
fixed, processed autoradiographically using the dipping film technique 
[15) with Il fo rd nuclear emulsion K2 (Ilford Nuclear Research, U.K.) , 
and t he labeling indices were subsequent ly calculated. 
Transglu.tamina.~e Assay 
The transglutaminase activity of facto r XIII was assayed by an 
adaptation of t he method fo r epidermal t ransglutaminase of Ogawa 
and Goldsmith [16] and Yuspa et al [17], which measures t he enzyme 
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catalyzed formation of •-('y glutamyl)ami no bonds between ["C)pu-
trescine and casein. This assay was carried out twice using different 
batches of l "C]putrescine. 
Briefly, 25 11 ! of variously t reated factor XIII preparation (1 IU/ml) 
was added to reaction mixtures consisting of 25 11l of a -casein (Sigma, 
U.K.), 251'1 of ["C]putrescine (Amersham) - 0.64 mM, 6.47 mCi/mmol 
on the first occasion and 0.64 roM, 6.51 mCi/mmol on the second 
occasion- and 125 11l of buffer. After incubation for 30 min at 37"C, 50 
11! of the reaction mixture was spotted on Whatman 3MM filter paper, 
washed with 10% trichloroacetic acid (BDH, Poole, U.K.), and the 
radioactivity was counted by a Model 1211 beta liquid scintillation 
counter (LKB Instruments, Croydon U.K.). The background radioac-
tivity from parallel assays, using medium without factor XIII, was 
subtracted from all samples. 
Before being used in the enzyme assay, the factor XIII was variously 
treated. For activation by thrombin, thrombin (final concent ration 10 
U/ml) was added to 10 IU/ml of factor XIII in 10% FCS-Dulbecco's 
MEM and incubated for 20 min at room temperature. For heat inacti-
vation, factor XIII was heated for 20 min at 60"C, fo llowed by thrombin 
activation in one experiment. For immunoprecipitation, 1 IU of factor 
XIII was treated with 0.2 ml of nondiluted, 4 times diluted, or 16 times 
diluted rabbit anti-factor XIII-S antiserum (Behringwerke AG) or with 
0.2 ml of nondiluted normal rabbit serum as control. After incubation 
for 30 min at 37"C, the precipitate was removed by centrifugation. All 
samples were adjusted to 1 IU/ml of factor XIII with 10% FCS-
Dulbecco's MEM and then used in the assay. 
Control Experiments 
To study the specificity of the effects of factor XHI in the inhibition 
of cell migration, we examined call migration from floating ex plants in 
medium supplemented with factor XIII which had been dialyzed against 
saline at 4"C overnight or heated at 60"C for 20 min. Cell growth in 
epidermal cell culture with dialyzed factor XIII was also studied. 
RESULTS 
Fig 1 shows the results of epidermal cell migration from 
floating explants that were treated with fibrinogen and cultured 
in medium supplemented with 10% FCS. The factor XIII 
preparation clearly had an inhibitory effect on cell migration 
in a dose-dependent fashion both in medium with a high 
calcium ion (Ca++) concentration (Ca++ containing Dulbecco's 
MEM and 10% FCS at 1. 7 mM concentration) and in medium 
with a low Ca++ concentration (Ca++_free MEM and 10% FCS 
at 0.4- mM) . This inhibitory effect was also observed when the 
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FIG 1. Epidermal cell migration from fl oati ng explants pretreated 
with fibr inoge n and incubated for 2 days in medium containing high 
or low concentrations of calcium and supplemented with 10% FCS. 
The number of migrated cells is expressed as the mean value ± SEM 
of 5 sections each from 5 different experiments. 
Vol. 83, No. 6 
TABLE I. Epidermal cell migration from floating and attached skin 
explants in the absence of fibr inogen 
Factor XIII (I U/ml) 
Experiments ca++ concentration 
0 0.1 
Floating High Ca++a 31.0' 28.7 
explants Low Ca++b 65.0 36.7 
Attached High Ca++ 3.0d 1.57 
explants Low Ca++ 0. 79 0.11 
"High Ca++: Dulbecco's MEM + 10% FCS (1.7 mM) . 
bLow Ca++: Ca++ -free MEM + 10% FCS (0.4 mM). 
1.0 
10.7 
2.0 
0.17 
0.38 
10 
1.7 
1.0 
0 
0 
' Results indicate the number of migrated cells from both edges of 
each explant: mean value of 2 explants. 
d Results indicate the area of migrated cells (mm2 /explant): mean 
value of 3 explants. 
FIG 2. Epidermal cell migration from the edge of the ep;dermis onto 
the dermis of the floating skin explant cultured in the medium contain-
ing facto r Xlll at 0.1 IU/ ml (H&E stain, X 200). 
previous fibrinogen treatment was omitted (Table I, upper 
rows). In the organ culture system that we have used, FCS is 
necessary for migration to occur. 
T o examine the effect of the factor XIII preparation at a 
much lower concentration of Ca++, we attempted to reduce the 
Ca++ concentration of FCS by means of a chelating resin 
(Chelex 100, Bio Rad Laboratory, U.S.A.) . However, when we 
observed floating ex plants cultured with Ca++ -free MEM sup-
plemented with 10% Chelex-treated FCS, (final Ca++ concen-
tration 0.01 mM), pemphigus-like cell disaggregation appeared 
and became prominent in the suprabasal zone of the epidermis 
of all samples, so that cell migration was difficult to observe. 
Fig 2 shows cell migration from a free-floating explant cultured 
in t he medium containing factor XIII at a concentration of 0.1 
IU/ml. 
In the experiments investigating epidermal cell migration 
from attached explants that were treated with fibrinogen and 
cultured in the presence of FCS, the factor XIII preparation 
a lso showed a clear inhibitory effect (Fig 3). As with the free-
floating explants, this effect was independent of the Ca++ 
concentration. This effect was also observed when previous 
fibrinogen treatment was omitted (Table I, lower rows). In t h e 
absence of FCS, cell migration was greatly reduced. 
To examine t he effect of the factor XIII preparation on 
epidermal cell growth as well as on cell migration, we used an 
epidermal cell culture system. The growth of epidermal cells 
after 1 week 's cultivation in the presence of factor XIII was 
considerably reduced in a dose-dependent manner (Table II, 
upper row). Labeling indices were also reduced in a dose-
dependent fashion (Table II, lower row). 
The transglutaminase activity of t he factor X III preparation 
was measured by means of [' 4C]putrescine incorporation into 
casein (Table III). The factor XIII preparation was found to 
possess a transglutaminase activity wit hout activation by 
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FIG 3. Epidermal cell migration from attached explants pretreated 
with fibrinogen and incubated for 7 days in medium containing high 
or low concentrations of calcium and supplemented with 10% FCS. 
The area of migration is expressed as the mean value ± SEM of 6 
explants from 2 different experiments. 
TABLE II. Cell growth 1:n. epidermal cell culture 
Factor Xlll (IU/ ml) 
Measurements 
0 0.01 0.1 1.0 10.0 
Number of cells cultured with nondialyzed 
factor XIII preparation (% of culture 100 92.0 81.8 55.6 16.4 
without factor XJII) " 
Number of cells cultured with dialyzed fac· 
tor XIII preparation (% of culture with- 100 89.5 69.7 50.4 35.7 
out factor XIII)b 
Labeling indices( %)' 30.2 16.9 16.8 9.3 0 
a Mean value of 5 different experiments. 
b Result of 1 duplicate experiment. Factor XIII preparation was 
dialyzed against saline at 4 ·c overnight. 
c Result of 1 duplicate experiment. Data show (number of radiola-
beled cells/total number of cells) X 100. 
TABLE lll . Results of tran.sglutamin.ase activity of the fa ctor XIII 
preparation. 
Treatment of factor 
Xlll preparation 
No treatment 
Thrombin activation 
Heat treatment at 60"C for 20 
min 
Heat tre atment and thrombin 
activation 
Anti-factor XIII -A antiserum 
treatment 
1 X diluted antiserum 
4 X diluted antiserum 
15 X diluted antiserum 
Control (1 x diluted NRS' ) 
Experiment l 
(cpm) 
Experiment 2 
(cpm) 
0.025 IU factor XIII 0.02S IU factor X III 
130" 
914 
0 
NT 
0 
26 
56 
94 
103 
481 
NTb 
115 
NT 
NT 
NT 
NT 
• Background radioactivity from parallel assays using added medium 
without factor XIII was subtracted from all samples. 
b Not tested. 
c Normal rabbit serum. 
thrombin, a lthough t he activity was 15- 20% of the factor XIII 
fully activated by thrombin. The transglutaminase activity 
completely disappeared after heat treatment for 20 min at 60"C 
if it was not activated by thrombin. However, thrombin treat-
TABLE IV. Control experiments for epidermal cell migration from. 
floating explan.ts, using dialyzed or heat-treated factor XIII" 
Treatment of factor Factor Xlll (IU/ml) 
XIII 0 0.1 1.0 10 
No treatment 6870b 6640 4456 2238 
Dialysis against saline at 5588 4370 3060 
4"C overnight 
Heat treatment at 60"C for 5830 3048 3009 
20 min 
• Explants were cultured in Dulbecco's MEM + 10% FCS (Ca++ 
concentration= 1.7 mM) without fibrinogen treatment in the presence 
of variously treated factor XIII preparation. 
b Results indicate the area of migrating epidermal cells from both 
edges of each explant (pm2 /explants): mean value of 4 explants. 
ment of heated factor XIII could partially restore the transglu-
taminase activity. The treatment of 1 IU of factor XIII by 0.2 
ml of antifactor XIII-S antisera completely abolished the trans-
glutaminase activity. With progressive dilution of the anti-
serum, the transglutaminase activity was restored. 
To examine t he specificity of the effect of t he factor XIII 
preparation, we used a preparation that had been dialyzed 
against saline at 4 ·c overnight. After exhaustive dialysis, the 
factor XIII preparation still showed t he inhibitory effect both 
on cell migration from floating explants (Table IV) and on cell 
growth in epidermal cell culture (Table II, middle row). 
When we used a factor XIII preparation that had been 
previously heated at 60oC for 20 min in a floating explant type 
experiment, the inhibitory effect was still evident (Table IV) . 
In further experiments we attempted to use factor XIII immu-
noprecipitated by anti-factor XIII-S antiserum and anti-factor 
XIII-A antiserum (Behringwerke AG) in a free-floating explant 
type experiment. However, even though the mixture of factor 
XIII and antisera was dialyzed after precipitation, clear dermal-
epidermal separation was observed in all explants and no 
epidermal cell migration could be seen, the cause of which was 
uncertain, although the presence of an excess amount of anti-
body or preservatives remaining after dialysis may have been 
responsible. 
DISCUSSION 
In both kinds of in vitro skin explant culture, the factor XIII 
preparation had a dose-dependent inhibitory effect on epider-
mal cell migration. The effect was obvious even in explants 
cultivated in physiologic concentrations of factor XIII (1 IU/ 
ml, i.e., the same concentration as in human plasma). The 
factor XIII preparation suppressed epidermal cell migration in 
both t he presence and absence of fibrin-the prime substrate 
of factor XIII. The effect appeared to be independent of the 
Ca++ concentration when we compared the effect at 1.7 mM 
and 0.4 mM Ca++ concentration. However, it should be noted 
that it was not possible to remove Ca++ completely because of 
the necessary presence of FCS in the medium to promote cell 
migration. 
Furthermore, our attempts to reduce t heCa++ concentration 
of FCS by means of a chelating resin fai led, because such 
cultural conditions with very low Ca++ concentrat ion (0.01 mM) 
were found to induce a pemphigus-like cell disaggregation in 
t he epidermis of skin explants. 
When we used the factor XIII preparation in epidermal cell 
cultures where the concentration of Ca++ was further lowered 
(0.2 mM), it also inhibited cell proliferation as assessed by both 
cell number and t he t hym idine autoradiographic labeling in -
dices of epidermal cells cultured for 1 week . However, it is not 
certain whether this reduced proliferation was induced by a 
direct effect of the factor XIII preparation on mitotic activity 
or via a secondary effect fo llowing the inhibition of cell migra-
tion on the dish. 
The assay for transglutaminase activity using [14C]putrescine 
incorporation into casein confirmed that the factor XIII prep-
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aration used had transglutaminase activity without previous 
thrombin treatment, although the activity was 15- 20% of that 
when fully activated by thrombin. Moreover, immunoprecipi-
tation of factor XIII in the preparation with specific anti-factor 
XIII antiserum abolished the transglutaminase activity and 
confirmed that factor XIII itself exerted this activity. 
In the first control experiment we dialyzed the factor XIII 
preparation against saline. Because the dialyzed factor XIII 
also showed the inhibitory effect on both cell migration from 
floating explants and cell growth in cell culture, it seemed 
unlikely that any dialyzable small molecules that may have 
contaminated the preparation were responsible for the inhibi-
tory effects. Factor XIII preparations heated to 6o·c for 20 
min showed no transglutaminase activity as reported by Lorand 
[18]; however, heat-treated factor XIII preparation still showed 
inhibition of cell migration from floating explants. Considera-
ble transglutaminase activity was restored to heat-inactivated 
factor XIII by thrombin treatment. It is possible that the heated 
factor XIII preparation still had a masked transglutaminase 
activity, only becoming evident during incubation with the skin 
explants. Other possibilities are that the inhibitory effect ob-
served is due to contamination of the preparation by large or 
even some small molecules which were not removed by dialysis 
and are heat stable, or that factor XIII in the preparation 
exerted effects not via its transglutaminase activity but via 
other mechanisms. 
In order to examine the specificity of the inhibitory effect 
further, we attempted to use a factor XIII preparation which 
had been immunoprecipitated by specific anti-factor XIII anti-
sera in floating explant type experiments. However, the addi-
tion of factor XIII antiserum mixture to the medium consist-
ently induced dermal-epidermal separation by an unknown 
mechanism and this phenomenon prevented us from observing 
cell migration. 
Taken all together, the results indicate that the factor XIII 
preparation has an inhibitory effect on epidermal cell migration 
and/or cell proliferation. At present there is no indication of 
the mechanism(s) involved, although several possibilities 
should be considered. Factor XIII in the preparation could 
inhibit cell migration by a direct effect on cell surface proteins 
[19] or on cytoplasmic actin filaments [20] via its transglutam-
inase action. This transglutaminase action may also affect 
epibolin (or other similar proteins), the plasma protein that 
appears to promote epidermal cell movement [21,22]. Yet an-
other possibility that should be considered concerns the poten-
tial for factor XIII to promote the differentiation of epidermal 
cells via its transglutaminase effect, inhibiting further move-
ment and proliferation [23,24]. However, it is also possible that 
factor XIII has a nonspecific adverse action on epidermal cells 
besides its transglutaminase activity. 
These results would not support the use of factor XIII (or at 
least this factor XIII preparation) to promote the early stages 
of wound healing in which reepithelialization is important. 
However, it should be noted that we do not have evidence that 
factor XIII has similar effects in vivo. Previous reports have 
been concerned mainly with the action of the material on 
connective tissue repair during the later stage of wound healing. 
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Further work on the mechanism of the migration-inhibiting 
effect of factor XIII is now under way. 
We are grateful to the Smith and Nephew Foundation for their grant 
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